Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors|
|Abstract:||A series of S-triazolyl .alpha.-mercaptoacetanilides having N-(.alpha.-mercaptoacetyl) p amino benzoic acid derivatives. ##STR00001## are provided, where Q is CO.sub.2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.|
|Inventor(s):||Girardet; Jean-Luc (San Diego, CA), Koh; Yung-Hyo (Irvine, CA), De La Rosa; Martha (Durham, NC), Hong; Zhi (Irvine, CA), Lang; Stanley (Laguna Niguel, CA)|
|Assignee:||Ardea Biosciences, Inc. (San Diego, CA)|
|Filing Date:||Dec 06, 2011|
|Claims:||1. A method of inhibiting HIV reverse transcriptase, the method comprising contacting HIV reverse transcriptase with a compound of formula 1: ##STR00106## wherein: R.sup.1 is Cl, Br, I, CH.sub.3, CF.sub.3, CHF.sub.2 or CH.sub.2F; R.sup.3 is H or CH.sub.3; R.sup.o is Cl, Br, CF.sub.3 or methyl; X is O or NH; R.sup.2 is H, a pharmaceutically acceptable cation or C.sub.1-3 alkyl, when X is O; or XR.sup.2 is NHCH.sub.2CH.sub.2COOR.sup.13 or NHCH(R.sup.12)COOR.sup.13; where R.sup.12 is C.sub.1-4 alkyl or aryl-C.sub.1-4 alkyl; and R.sup.13 is a pharmaceutically acceptable cation or C.sub.1-3 alkyl; Ar is selected from the group consisting of (a), (b), (c) and (d): ##STR00107## wherein R.sup.P is selected from the group consisting of methyl, ethyl, propyl, isopropyl, cyclopropylmethyl, and C.sub.3-6 cycloalkyl; R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of H, F, Cl, Br, CF.sub.3, CFH.sub.2, CF.sub.2H, ethyl, isopropyl, cyclopropyl, OCH.sub.3, OH, OCF.sub.3, NH.sub.2 and NHCH.sub.3; R.sup.7 is selected from the group consisting of Cl, Br, I, CF.sub.3, OCH.sub.3, isopropyl, cyclopropyl, tent-butyl, and cyclobutyl; and R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are independently H or CH.sub.3. |
2. The method of claim 1, wherein the HIV reverse transcriptase is a mutated reverse transcriptase.
3. The method of claim 2, wherein the mutated reverse transcriptase is a K103N, Y181C or Y188L mutant.
4. The method of claim 1, wherein the inhibition occurs in vitro.
5. The method of claim 1, wherein the inhibition occurs in vivo.
6. The method of claim 1, wherein the compound of formula 1 is 4-[2-(5-bromo-4-[4-cyclopropyl-7-methoxynaphthalen-l-yl]-4H-1,2,4-triazol- -3-ylthio)acetamido]-3-chlorobenzoic acid.
7. The method of claim 5, wherein the compound of formula 1 is 4-[2-(5-bromo-4-[4-cyclopropyl-7-methoxynaphthalen-l-yl]-4H-1,2,4-triazol- -3-ylthio)acetamido]-3-chlorobenzoic acid.
8. The method of claim 1, wherein the compound of formula 1 is a pharmaceutically acceptable salt of 4-[2-(5-bromo-4-[4-cyclopropyl-7-methoxynaphthalen-1-yl]-4H-1,2,4-triazol- -3-ylthio)acetamido]-3-chlorobenzoic acid, R.sup.2 being a pharmaceutically acceptable cation.
9. The method of claim 1, wherein the compound of formula 1 is a methyl, ethyl or propyl ester of 4-[2-(5-bromo-4-[4-cyclopropyl-7-methoxynaphthalen-l-yl]-4H-1,2,4-triazol- -3-ylthio)acetamido]-3-chlorobenzoic acid, R.sup.2 being methyl, ethyl, or propyl.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.